Baricitinib plus remdesivir for hospitalized adults with Covid-19

…, GA Deye, W Dempsey, SU Nayak… - … England Journal of …, 2021 - Mass Medical Soc
Background Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated
inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, …

Homologous and heterologous Covid-19 booster vaccinations

…, JI Archer, S Crandon, SU Nayak… - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled …

…, V Ghazaryan, W Dempsey, SU Nayak… - The lancet respiratory …, 2021 - thelancet.com
Background Functional impairment of interferon, a natural antiviral component of the
immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to …

[PDF][PDF] Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

…, KM Neuzil, DS Stephens, DJ Post, SU Nayak… - Cell Reports …, 2022 - cell.com
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

…, V Ghazaryan, W Dempsey, SU Nayak… - The lancet respiratory …, 2022 - thelancet.com
Background Baricitinib and dexamethasone have randomised trials supporting their use for
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

…, DC Montefiori, M Makowski, DJ Smith, SU Nayak… - Nature medicine, 2023 - nature.com
Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection wanes over time, requiring updated boosters. In a phase 2, open-label, …

[HTML][HTML] Heterologous SARS-CoV-2 booster vaccinations–preliminary report

…, CM Posavad, JI Archer, S Crandon, SU Nayak… - MedRxiv, 2021 - ncbi.nlm.nih.gov
Background: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective,
breakthrough infections are occurring. Booster vaccinations have recently received emergency …

SARS-CoV-2 variant vaccine boosters trial: preliminary analyses

…, S Türeli, M Makhene, S Crandon, M Lee, SU Nayak… - MedRxiv, 2022 - medrxiv.org
Background Protection from SARS-CoV-2 vaccines wanes over time and is compounded by
emerging variants including Omicron subvariants. This study evaluated safety and …

Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2 …

…, L Komarow, MP Nikolich, TP Lodise, SU Nayak… - Trials, 2022 - Springer
Background Bacteriophages (phages) are a promising anti-infective option for human disease.
Major gaps remain in understanding their potential utility. Methods This is a randomized, …

Use of cooling centers to prevent heat-related illness: summary of evidence and strategies for implementation

…, RS Noe, E Grossman, M Hawkins, SU Nayak… - 1917 - stacks.cdc.gov
Extreme heat is a major public health concern in the United States. The trend of increasing
frequency and duration of heat events (“heat waves”) is expected to continue in the future. …